Introduction
H2a and H2b. The position of the H2a and H2b helices is such that every surface exposed side 1 chain of both helices within the binding site directly contacts NKG2D ( Figure 2B ). Only two 2 contacts are found outside of H2a and H2b, Ile49 and Arg66. Both of these residues are within 3 the α 1 domain but lie outside of the H1 helix.
4
Twelve OMCP residues contact eighteen NKG2D residues to form a mixture of bond 5 types ( Table 2 ). Three residues in each NKG2D half-site are known as core binding residues 6 because they make contacts with all known host NKG2DLs. The core residues of NKG2D 7 subunit A (NKG2D A ) (Tyr152, Tyr199, Met184) form two hydrogen bonds and make extensive 8 hydrophobic contacts with OMCP residues. The core residues of NKG2D A contact four OMCP 9 residues and the most critical of these residues is Phe122. Phe122 makes multiple hydrophobic 1 0 contacts with all three NKG2D A core residues, including pi-stacking with Tyr152. Phe122 also 1 1 forms a backbone-to-sidechain hydrogen bond with Tyr152. Interestingly, OMCP is the first 1 2 NKG2D ligand not to utilize all six NKG2D core-binding residues, with only Met184 and Tyr152 1 3 of NKG2D subunit B (NKG2D B ) contacting OMCP. NKG2D B Met184 and Tyr152 each make a 1 4 single hydrogen bond and hydrophobic contacts with OMCP residues. Two OMCP residues, 1 5
Trp127 and Asp132, make contacts with both NKG2D protomers. OMCP Trp127 forms a 1 6 hydrogen bond to Lys150 of NKG2D A and makes several hydrophobic contacts with Leu148 of 1 7 NKG2D B , Lys150 and Ser151 of NKG2D A . OMCP Asp132 forms a hydrogen bond with Tyr152 1 8 of NKG2D B and a salt bridge with Lys150 of NKG2D A ( Figure 3A ).
9
Due to the high affinity of the OMCP-NKG2D interaction we harnessed a high throughput 2 0 in vitro selection approach to find NKG2D-binding null mutants (Table S1 ). The results of the 2 1 screen identified D132 as an important residue for disrupting NKG2D binding. We then 2 2 generated OMCP with the D132R mutation in an attempt to completely ablate NKG2D binding.
3
The D132R mutant protein was unable to bind to NKG2D-expressing cells, but retained binding 2 4
to FcRL5-expressing cells ( Figure 3B ). This mutation is likely to cause significant steric clashes, as well as disrupting both interactions made by Asp132 to NKG2D A Lys150 and NKG2D B 1 Tyr152 ( Figure 3A ).
The role of OMCP receptors in CPXV infection. We generated a recombinant CPXV that 4 expressed the D132R mutant OMCP to isolate the effect of OMCP binding to NKG2D from 5 binding to FcRL5. A multi-step growth curve of (D132R) OMCP CPXV demonstrated identical 6 replication growth kinetics to WT CPXV (Fig. S1 ). Cowpox and its close relatives variola virus, 7 vaccinia virus, and monekeypox can be spread via contact and aerosol transmission [50]; 8 therefore, we choose to study the role of OMCP during acute intranasal (i.n.) infection. Using 9 our series of WT OMCP expressing CPXV, OMCP-deficient CPXV (ΔV018), and (D132R) 1 0 OMCP mutant expressing CPXV in combination with WT, NKG2D-deficient, and FcRL5-1 1 deficient mice, we were able to delineate the impact of OMCP on NKG2D-and FcRL5-1 2 expressing cells during CPXV infection in vivo.
Mice were infected i.n. with 2.5x10 4 pfu/mouse of WT, OMCP-deficient, or D132R CPXV 1 4 virus. Infection with WT CPXV resulted in similar mortality in WT, NKG2D-deficient, and FcRL5-1 5 deficient mice ( Fig. 4 solid lines) . However, the complete loss of OMCP ( Fig. 4 , dashed lines) 1 6 rendered CPXV severely attenuated in WT and FcRL5-deficient mice, while OMCP-deficient 1 7
CPXV infection in NKG2D-deficient mice remained similarly lethal as WT CPXV. These results 1 8
illustrated that under normal circumstances (i.e., WT CPXV infection in WT mice), OMCP is able 1 9
to effectively abrogate activation through the NKG2D receptor, rendering WT CPXV as lethal in bacterial-derived OMCP [37-39], OMCP produced in mammalian cells would be modified by N-6 linked glycosylation. OMCP is glycosylated at N12, one of its two putative N-glycan sites, when 7 produced in mammalian cells ( Fig S3A) . The absence of a phenotype for FcRL5 in mice led us 8 to confirm whether mammalian-derived, glycosylated OMCP binds to FcRL5-expressing cells.
9
To test whether glycosylation would affect OMCP receptor binding, we compared binding of 1 0 bacterially-expressed or mammalian-expressed OMCP to Ba/f3 cells expressing NKG2D or 1 1 FcRL5 (Fig. 5A ). Regardless of source, OMCP bound to NKG2D-expressing cells. In contrast 1 2 to bacterially-expressed OMCP, mammalian-expressed OMCP did not bind to FcRL5-1 3 expressing cells. To confirm whether the difference in FcRL5 binding was due to glycosylation, 1 4 mammalian-expressed OMCP was treated with EndoF to remove the N-linked glycan. The 1 5 deglycosylated protein gained the ability to interact with FcRL5. Next we tested the binding of Structural basis for species-specific affinity. Previously, the 14-fold higher affinity of OMCP for human vs murine NKG2D was mapped to three amino acid substitutions in the β 5'-β5 loop of 2 NKG2D, abbreviated L2 [38] . In addition to the substitutions themselves (I182V, M184I and 3 Q185P), the position of the loop between NKG2D orthologs differs. L2 in human NKG2D is bent 4 towards the center of the concave binding cavity compared to L2 of murine NKG2D.
5
Superimposition of murine NKG2D onto the human NKG2D-OMCP structure reveals that the 6 contacts between OMCP and Met184 (mNKG2D residue I200) in NKG2D B and between Met184 7 (I200) and Glu185 (P201) in NKG2D A would be altered due to the different position of the 8 murine β 5'-β5 loop ( Figure 6A-B ). This alteration would disrupt contacts with three residues in 9 OMCP H2a, three residues in H2b and Arg66 within the α 1 domain. Of the contact residues of 1 0 L2, Met184 makes the most significant contacts in both NKG2Ds (Table 2)( Figure 6C ).
1
Critically, of the 58 NKG2D sequences available in GenBank, 54 conserve the Met184 and 1 2
Glu185 found in the high affinity human NKG2D ( Figure 6D ).
3
Eighteen OMCP variants have been described between different CPXV and MPXV 1 4 strains [51] . In this study, we have crystallized OMCP from the Brighton Red strain of CPXV 1 5 which has >60% sequence identity with the highly conserved sequence of the other 17 OMCP 1 6 variants, collectively termed OMCP mpx . Of the 12 OMCP contact residues observed, 9 are 1 7 identical to OMCP mpx . Of the remaining contacts, all three are conservative hydrophobic 1 8 substitutions (I49L, T118I and M135I) ( Figure 7 ). OMCP mpx binds to NKG2D and the 1 9 substitutions in the NKG2D contact residues are unlikely to grossly affect the affinity of 2 0 OMCP mpx for NKG2D [37]. OMCP binds NKG2D with a novel orientation. We therefore asked whether OMCP could serve 2 1 as a NKG2D agonist in the context of the cell membrane, analogously to host NKG2D ligands.
2
Since OMCP is a secreted protein, an artificially cell-associated OMCP was constructed by 2 3 using a heterologous GPI anchor from Thy1.1 [37] ( Figure 5D ). To measure NKG2D-mediated 2 4 cell killing, we stably transduced Ba/F3 cells with retroviral vectors expressing either the OMCP-
5
Thy1.1 construct or host NKG2DLs. OMCP-Thy1.1-expressing target cells were killed equivalently to host NKG2DL-transduced target cells, indicating that despite its altered binding 1 orientation, cell-associated OMCP was able to activate NKG2D signaling ( Figure 8E ). Thus, 2 OMCP must be secreted lest it active NKG2D-effector functions itself, despite potential loss of 3 efficacy due to diffusion. Pathogens deploy multiple mechanisms to subvert the host immune response. We have 7 previously reported that the poxvirus protein OMCP binds to two different murine immune 8 receptors, NKG2D and FcRL5. Here, we demonstrate for the first time that OMCP facilitates 9 cowpox virus virulence in vivo thorough antagonism of NKG2D. Surprisingly, we found no 1 0 impact of FCRL5 in vivo during infections with OMCP-deficient CPXV or D132R CPVX 1 1
(expressing OMCP with a mutation selectively abrogating binding with NKG2D). Investigations
2
into the absence of a phenotype in the FCRL5-deficient mice revealed that mammalian-derived, 1 3 glycosylated OMCP did not bind to FCRL5 in contrast to bacterially-expressed OMCP.
4
Treatment of the mammalian-derived OMCP with EndoF removed the N-linked glycan and 1 5 exposed a portion of OMCP that would not be present during in vivo infections. Surprisingly, this 1 6 normally hidden surface of OMCP was able to interact with FcRL5-expressing cells. This While many viruses have adopted a general mechanism of NKG2D-sabotage by trying 1 to retain multiple host-encoded NKG2D ligands within the infected cell, CPXV and MPXV take 2 the very different approach of targeting NKG2D directly. Since NKG2D is monomorphic, this 3 mechanism has the significant advantage of requiring a single protein to prevent NKG2D 4 recognition of the infected cell. The large number of sequence-divergent host NKG2DLs and 5 their associated polymorphisms are thought to be driven by selection from pathogen-encoded 6 NKG2DL antagonists [14] . Likewise, viral NKG2L antagonists are under selective pressure from 7 the diverse host NKG2DLs in a continual cycle of adaptation. Due to the need to recognize 8 multiple NKG2DLs, NKG2D has a limited mutational space to adapt. The limited ability of 9 NKG2D to mutate is yet another advantage of OMCP directly targeting NKG2D, instead of 1 0
NKG2DLs.
1
Similarly to OMCP, some cancer cells shed host NKG2DLs to create their own soluble 1 2 NKG2D antagonists. However, this strategy has the additional benefit of removing host 1 3 NKG2DL from the surface of cancer cells. In contrast, CPXV and MPXV lack a known 1 4 mechanism of blocking host NKG2DL surface expression. Secreted OMCP must then be able 1 5
to compete efficiently against the high local concentration of multiple host NKG2DLs on the 1 6 infected cell, as well as against diffusion away from the infected cell. One possible way to 1 7 increase OMCP's ability to compete with host ligands would be to increase the avidity of OMCP 1 8 by having multiple NKG2D-binding domains. However, a multimeric OMCP could crosslink 1 9
NKG2D and potentially trigger NKG2D-mediated killing. Therefore, secreted OMCP must be 2 0 monomeric to prevent aberrant NKG2D signaling. Thus to compensate for these deficiencies, 348 and 54 seconds, respectively, compared to half-lives of 1.5-18 seconds for most NKG2DLs 2 5 [38, 45, 55] . Indeed, the increased half-life for NKG2D allows OMCP to effectively antagonize NKG2D-mediated immunity in our murine infection models despite the lower affinity of the 1 murine NKG2D receptor for OMCP compared to human NKG2D receptor. CPXV infections in 2 primates or rodents that express the higher affinity NKG2D receptor would likely be protected 3 from NKG2D-mediated immunity by OMCP to a greater degree.
4
To understand the molecular basis for the long half-life of OMCP for NKG2D, we 5 previously determined the structure of OMCP alone, and here, we report the structure of OMCP 6 bound to NKG2D. The structure of OMCP alone was grossly similar to that of host NKG2D 7 ligands, containing an atypical MHCI-like platform domain. Host NKG2D ligands bind with the 8 helices of their platform domains oriented diagonally within the symmetric binding groove of 9 NKG2D. Thus it was expected that OMCP was a viral mimic of host NKG2D ligands and would 1 0 interact with NKG2D analogously.
1
The structure of OMCP-NKG2D instead revealed a novel orientation for an NKG2D OMCP reveals how the MHCI-like platform used by host ligands can be adapted by a pathogen 2 0 to enhance NKG2D binding.
Since host NKG2DLs and OMCP have a similar MHCI-like platform, it is reasonable to 2 2 wonder why no host ligand has evolved an analogous high-affinity interaction with NKG2D. One 2 3 likely reason is that the host immune response must be carefully calibrated to balance the need 2 4 for protection against the threat of autoimmunity. Since the expression of NKG2DLs on the cell 2 5 surface signals for effector functions, even a small amount of high affinity host ligand on the cell surface could trigger an immune response, and the resulting tissue damage could be 1 deleterious for the host. Indeed, NKG2D-expressing cells and/or aberrant expression of host 2 NKG2DLs have been implicated in diabetes, celiac disease and rheumatoid arthritis [56] [57] [58] [59] . maintained under specific pathogen-free conditions and used between 8 and 12 weeks of age.
7
Female mice utilized in survival studies were observed daily after infection for 28 days and 1 8 moribund mice were euthanized per institutional guidelines. 
1
All experiments were conducted in accordance with institutional guidelines for animal care and promoter was amplified and spliced to another PCR product encoding the E. coli gpt sequence.
7
The final product was cloned into plasmid pUC19 to create pUC19 p7.5 gpt. OMCP was then 1 8
amplified in two fragments in order to insert two tandem early termination codons. This product 1 9
was cloned into pUC19 7.5 gpt to create pUC19 p7.5 gpt OMCPSTOP. The revertant plasmid 2 0 pUC19 p7.5 gpt OMCP was generated by excising the OMCPSTOP sequence and replacing it 2 1
with wild-type OMCP. OMCP D132R mutant CPXV was generated in a similar manner with 2 2 primers to insert a point mutation at D132. The mutated D132R construct was also spliced to E.
Confluent CV-1 cells were then infected with CPXV (for CPXV Δ V018 or D132R generation) or 
Arg138 
